Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $37.17 Average Target Price from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has earned a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $37.17.

KNSA has been the topic of several analyst reports. Wedbush reiterated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the transaction, the chief operating officer now owns 88,975 shares in the company, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,879 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total transaction of $205,104.90. Following the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at $540,124.20. This represents a 27.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,766 shares of company stock worth $2,011,735 over the last three months. 54.57% of the stock is currently owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new position in Kiniksa Pharmaceuticals in the third quarter worth $354,000. FMR LLC raised its stake in shares of Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after buying an additional 694,928 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 21,721 shares of the company’s stock worth $543,000 after acquiring an additional 12,239 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at about $189,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Kiniksa Pharmaceuticals in the third quarter valued at about $1,105,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $19.90 on Monday. Kiniksa Pharmaceuticals has a one year low of $16.56 and a one year high of $28.15. The company’s fifty day moving average price is $20.96 and its two-hundred day moving average price is $21.69. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -142.13 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period in the prior year, the company posted $0.35 EPS. The business’s revenue was up 46.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.